TransThera Sciences (Nanjing) (HKG:2617) obtained approval for a phase II trial of TT-01488 tablets, according to a Wednesday Hong Kong bourse filing.
The drug will be tested in combination with anti-CD20 monoclonal antibody for the treatment of mantle cell lymphoma.